Category: MAKO Surgical Corp.
Mako Surgical reports lower losses, meets Wall Street's earnings expectations and affirms its guidance for the rest of the year, sending shares up today.
Mako Surgical (NSDQ:MAKO) shares are up today after the medical device company reported lower 1st-quarter losses and affirmed its guidance for the rest of the year.
Stanmore Implants hands its robotic surgery technology over to Mako Surgical and agrees to exit the field in exchange for a cash settlement and Mako's promise to drop its patent infringement complaints.
Stanmore Implants agreed to exit robotics entirely in order to settle patent infringement complaints filed by Mako Surgical (NSDQ:MAKO) over robotic surgery technology
A judge hands Mako Surgical an injunction against Blue Belt Technologies and ex-Mako sales vice president Jeff Gellman, ending a breach of contract lawsuit between the robotic surgery companies.
Mako Surgical (NSDQ:MAKO) won an injunction restricting a former sales executive's ability to work for rival Blue Belt Technologies in a breach of contract lawsuit leveled between the robotic surgery companies.
Mako Surgical sues Stanmore Implants for patent infringement over robotic surgery patents and files a complaint with the U.S. International Trade Commission.
Mako Surgical (NSDQ:MAKO) filed a pair of lawsuits against Stanmore Implants alleging patent infringement over robotic surgery technology, and filed a complaint with the U.S. International Trade Commission over the alleged violations.
Shares of robotic surgery device makers, Intuitive Surgical, Mako Surgical and Hansen Medical all slid today on Wall Street after the Massachusetts Board of Registration in Medicine issues a warning on the risk of adverse events during the procedures.
Shares of the leading robotic surgery device makers all fell today, after a Massachusetts medical board issued an advisory to surgeons warning of possible risks with the cutting-edge technology.
The benefits and risks – not to mention the costs – of robot-assisted surgery make for hot debate on Wall Street and among physicians.
By Stephen Simpson